1. Blockage of the NLRP3 inflammasome by MCC950 inhibits migration and invasion in adenomyosis.
- Author
-
Liu Y, Jiang Z, Zhang L, Tian W, Lin A, and Li M
- Subjects
- Adult, Animals, Female, Humans, Mice, Middle Aged, Cell Movement drug effects, Cell Proliferation drug effects, Epithelial-Mesenchymal Transition drug effects, Furans pharmacology, Sulfonamides pharmacology, Sulfones pharmacology, Adenomyosis metabolism, Adenomyosis pathology, Adenomyosis drug therapy, Endometrium metabolism, Endometrium pathology, Endometrium drug effects, Indenes pharmacology, Inflammasomes metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, NLR Family, Pyrin Domain-Containing 3 Protein antagonists & inhibitors, NLR Family, Pyrin Domain-Containing 3 Protein genetics
- Abstract
Research Question: Does the NOD-like receptor protein 3 (NLRP3) inflammasome have an effect in adenomyosis?, Design: Fresh-frozen endometrial tissues and paraffin specimens were obtained from endometrial tissues from patients with adenomyosis and controls. Western blot, quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were applied to assess expression of the NLRP3 inflammasome components. Primary eutopic endometrial stromal cells were isolated from the uteri of patients with adenomyosis. After NLRP3 was knocked down using small interfering RNA, proliferation, invasion and epithelial-mesenchymal transition (EMT) were evaluated using EdU, CCK8, transwell assays and western blot. Importantly, a mouse model of adenomyosis was established to evaluate the effects of the NLRP3 inhibitor MCC950 on the formation of adenomyosis., Results: Expression of the NLRP3 inflammasome components was elevated in the ectopic or eutopic endometrium of patients with adenomyosis. NLRP3 knockdown inhibited migration, invasion and EMT in endometrial cells and primary endometrial cells (P < 0.0001). MCC950, which blocks the NLRP3 inflammasome, reduced migration and invasion of endometrial cells (P < 0.01) and primary endometrial cells (P < 0.0001) considerably. Importantly, in the mouse model of adenomyosis, MCC950 had a mitigating effect on the severity of adenomyosis (P < 0.01)., Conclusions: NLRP3 was found to enhance migration, invasion and EMT of human endometrial cells in adenomyosis. Notably, the NLRP3 inhibitor MCC950 reduced migration and invasion of endometrial cells effectively. Furthermore, in the mouse model of adenomyosis, MCC950 exhibited a therapeutic effect by alleviating the severity of adenomyosis., (Copyright © 2024 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF